Myring (Ethinylestradiol, Etonogestrel)

Ethinylestradiol/Etonogestrel, the active ingredients in Myring, are a combined estrogen‑progestogen presented as a vaginal ring for vaginal use. It provides hormonal contraception for women of reproductive age, preventing ovulation and pregnancy. GNH USA supplies Myring as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Myring, a combined estrogen‑progestogen vaginal ring, is used within the hormonal contraceptive pathway to prevent unintended pregnancy. - Contraception: Prevents ovulation and pregnancy in women of childbearing age. - Family planning: Offers a long‑acting, reversible hormonal method for birth control. - Menstrual cycle control: May reduce irregular bleeding and stabilize cycle length.

Myring may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of the breasts. - Headache: occasional throbbing or pressure sensation. - Vaginal irritation: redness or itching at the insertion site. - Spotting: irregular light bleeding between periods.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Stroke or myocardial infarction: rare cerebrovascular or cardiac events. - Hepatic adenoma: benign liver tumor formation. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Persistent abdominal pain: may indicate serious intra‑abdominal pathology.

Before prescribing Myring, clinicians should evaluate patient‑specific risk factors and provide counseling. - Assess thrombotic risk: avoid in women with a history of clotting disorders. - Screen for hypertension: monitor blood pressure regularly. - Evaluate liver function: contraindicated in severe hepatic disease. - Avoid smoking: especially in women over 35 years of age. - Review concomitant medications: consider potential drug interactions. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Myring can interact with several medicines that alter hormone metabolism or increase clotting risk.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may markedly reduce contraceptive efficacy. - Rifampin: accelerates hormone clearance, increasing failure risk. - Protease inhibitors (e.g., ritonavir): can raise hormone levels and heighten adverse‑event potential.

Moderate Interactions (Monitor Closely): - Broad‑spectrum antibiotics (e.g., tetracycline): may slightly diminish effectiveness. - St. John’s wort: herbal inducer that can lower hormone concentrations. - Azole antifungals (e.g., ketoconazole): may increase hormone exposure, requiring monitoring.